BACKGROUND: Echocardiographic quantitation of degenerative mitral regurgitation (DMR) is recommended whenever possible in clinical guidelines but is criticized and its scalability to routine clinical practice doubted. We hypothesized that echocardiographic DMR quantitation, performed in routine clinical practice by multiple practitioners, predicts independently long-term survival and thus is essential to DMR management.
RESULTS:
The cohort included 3914 patients (55% male) mean age (±standard deviation) 62±17 years with left ventricular ejection fraction 63±8% and median after routinely-measured effective regurgitant orifice area (EROA) [ . During follow-up (6.7±3.1 years), 696 patients died under medical management, and 1263 underwent mitral surgery. In multivariate analysis, routinely-measured EROA was associated with mortality (adjusted hazard ratio, 1.19; 95% confidence interval, 1.13-1.24; P<0.0001 per 10 mm 2 ) independently of left ventricular ejection fraction and end-systolic diameter, symptoms, and age/comorbidities. The association between routinely-measured EROA and mortality persisted with competitive risk modeling (adjusted hazard ratio, 1.15; 95% confidence interval, 1.10-1.20; P<0.0001 per 10 mm 2 ), or in patients without guideline-based class I/II surgical triggers (adjusted hazard ratio, 1.19; 95% confidence interval, 1.10-1.28; P<0.0001 per 10 mm 2 ) and in all subgroups examined (all P<0.01). Spline curve analysis showed that, compared with general population mortality, excess mortality appears for moderate DMR (EROA ≥20 mm 2 ), becomes notable at EROA ≥30 mm 2 , and steadily increases with higher EROA levels (eg, higher EROA levels beyond the 40 mm 2 threshold).
D
egenerative mitral regurgitation (DMR) is frequent and defined by the presence of mitral prolapse as the cause of regurgitation. [1] [2] [3] Clinical guidelines underscore that determination of DMR severity is one of the first steps of clinical decision making and is an important predictor of clinical outcome. 4, 5 Echocardiographic guidelines emphasize that "characterization of severity of regurgitant lesions is among the most difficult problems" but also that "it is desirable for echocardiographers with experience in quantitative methods to determine quantitatively the degree of regurgitation." 6, 7 These guidelines also provide specific thresholds for severe regurgitation. This quantitative approach is supported by our previous proof-of-concept study, which demonstrated the link between quantified regurgitation severity and outcome. 8 However, the issue of regurgitation quantitation, particularly in DMR, is challenged on multiple fronts.
Indeed, different quantitative studies suggested different thresholds for severe mitral regurgitation (MR), 9, 10 and the subsets incurring excess mortality remain widely disputed. 11, 12 Because our proof-of-concept study included various MR causes, with DMR vastly dominating severe MR, conceivably the degenerative cause by itself may be responsible for poor outcomes rather than severe MR. 8 More recently, technical studies challenged accuracy, 13 reproducibility, 14 and validity of Doppler echocardiographic regurgitation quantitation versus magnetic resonance imaging or 3-dimensional echocardiography. [15] [16] [17] However, the main concern is that few experts conducted the proof-of-concept studies, 8, 18, 19 and these quantitative methods have not been validated in routine practice. Therefore, the recommendation for routine clinical practice of obtaining quantitative MR measures that may be poorly feasible or prognostically insignificant 20 may place an unreasonable burden on practicing physicians. Hence, the crucial question (ie, the primary aim of this study) is whether quantitative DMR assessment is scalable to routine practice and provides measures that are independently associated with survival when measured by multiple physicians/ sonographers in day-to-day clinical practice. If this hypothesis is verified, then a secondary aim is to verify whether the individual values obtained by DMR quantitative assessment of effective regurgitant orifice area (EROA) or regurgitant volume provide prognostic information incremental to the MR grading as mild, moderate, or severe.
METHODS
Because of confidentiality issues, the datasets and study materials safeguarded by the health science department of Mayo Clinic cannot be made available to outside parties. All patients diagnosed with mitral valve prolapse using transthoracic echocardiography from 2003 to 2011 at Mayo Clinic Rochester were retrieved. We excluded patients <18 years of age, with denied research authorization or presenting with any of the following issues: ≥ moderate aortic regurgitation or stenosis, ≥ moderate mitral stenosis, previous valvular surgery, congenital heart disease, obstructive cardiomyopathy or restriction cardiomyopathy or pericardial constriction (patent foramen ovale or tricuspid regurgitation were not excluded). Among eligible patients, we excluded those without a clinical/ comorbidity assessment (clinical note unavailable). Hence, the initial population included 6068 patients, among whom 3914 had DMR quantified and constituted the main study cohort, and 2154 with purely qualitative DMR assessment formed the verification cohort to verify potential selection bias ( Figure I in the online-only Data Supplement). Because this is a lowrisk study, the written consent requirement was waved by the Mayo Clinic Institutional Review Board, which gave its approval for this study.
Vital signs (blood pressure, heart rate, height, and weight) were recorded at echocardiography. From the notes of patients' personal physicians, comorbid conditions were electronically retrieved with the Charlson index (a weighted index of the count of comorbid conditions) 21 and computed, and cardiac symptoms (eg, dyspnea, orthopnea, palpitations, angina, edema) were collected using natural language processing. Diagnosis of atrial fibrillation by ECG and biological data of interest were downloaded ≤3 months before diagnosis.
Clinical Perspective
What Is New? 
Follow-Up
Because mitral surgery has been previously demonstrated to eliminate excess mortality associated with DMR, 8, 24 our main outcome measure of interest was mortality under medical treatment (all-cause). Hence the follow-up time during which events were collected for this end point was between diagnosis and either mitral surgery (if performed) or last follow-up. Occurrence and dates of deaths were retrieved using Accurint, a proprietary resource gathering multiple national sources, at the end of 2015.
To ensure accurate mortality counts, the unoperated patients, alive based on Accurint data, were censored on December 31, 2014. Surgical procedures were retrieved using the Mayo Clinic surgical registry and by clinical notes for patients operated outside of Mayo Clinic. The type of mitral surgery (repair or replacement) was specified, as well as potential associated procedures. As per routine clinical practice, therapeutic management was decided by patients' personal physicians.
Statistical Analysis
Continuous data are expressed as mean±SD or median (interquartile range) according to distribution and compared using ANOVA or Wilcoxon test as appropriate. Qualitative data are expressed as percentages and compared using ANOVA or χ 2 test as appropriate. Survival is displayed using Kaplan-Meier curves and compared using log-rank test. The primary end point of survival under medical treatment was analyzed using Kaplan-Meier curves and Cox proportional hazards models. Atrial fibrillation, n (%) 590 (15) 68 (5) 166 (22) 184 (20) 172 (18) Diabetes mellitus, n (%) 271 (7) 59 (5) 67 (9) 88 (9) 57 (6) Hypertension, n (%) 1373 (35) 3156 (25) 349 (49) 399 (42) 289 (30) CAD, n (%) 992 (25) 182 (15) 224 (30) 283 (30) 303 (31) Symptoms, n (%) 1486 (38) 327 (26) 265 (35) 407 (43) 487 (50)
Hemoglobin, g/dL* 13.7±1.7 13.7±1.6 13.5±1.6 13.6±1.7 13.9±1.7
Creatinine, mg/dL* LVESD ≥40 mm, n (%) 417 (11) 30 (3) 50 (7) 131 (14) 206 (22) LVEF, %* 63±8 63±6 62±8 62±8 64±8
LVEF <60%, n (%) 907 (23) 276 (22) 210 (28) 248 (26) 173 (18) EROA, mm 
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The main analysis was performed within the whole quantitative cohort and was analyzed in 3 models using increasing depth of adjustment. Verification analyses were performed among the subset of asymptomatic patients with no other known MR-related risk factors by guidelines 4 (left ventricle ejection fraction >60%, left ventricular end-systolic diameter <40 mm, systolic pulmonary artery pressure ≤50 mm Hg, sinus rhythm). Subgroup analyses are presented as forest plots. The secondary end point was excess mortality under medical management, comparing observed mortality in the DMR cohort to expected mortality in the general population. Methods and results of competing models based on transitional modeling are presented in the appendix in the online-only Data Supplement. For all analyses, the α level was set at 0.05. All analyses were performed using JMP 10 and SAS software.
RESULTS

Patients' Characteristics
From 2003 to 2011, our cohort included 3914 patients diagnosed with isolated quantified DMR with all eligibility criteria. Baseline clinical/echocardiographic characteristics are displayed in Table 1 overall and by DMR grade (using EROA classes). Overall age was 62±17 years, with balanced sexes and usual prevalence of comorbid conditions associated with age, although generally infrequent and also ascertained by normal overall hemoglobin and creatinine levels. Ventricular and atrial dilatation was mild, coherent with a wide DMR range. Distributions among guideline-based quantitative DMR grades are indicated Table 1 . Usual trends for older age, male predominance, more symptoms, larger ventricle and atrium, and higher systolic pulmonary artery pressure with higher DMR grade are noted. Conversely, there was no trend for worse comorbidity, hemoglobin, or ejection fraction, and creatinine showed a minimal trend for an increase with increasing DMR degree.
Routine Quantitative MR Assessment Association to Survival Under Medical Treatment
Follow-up was 6.7 (4.3-9.3) years, during which 1263 patients underwent mitral surgery (1166 repairs, 97 replacements) and 835 patients died: 696 under medical treatment (end point of the study) and 139 after surgery. Overall cohort survival under medical treatment was 95±0.4% at 1 year, 83±0.7% at 5 years, and 69±1% at 10 years.
Ten Multivariable proportional hazard analysis used 3 levels of adjustment depth (Table 2) , first for age, sex, and Charlson index (model 1); second, adjusting additionally for guideline-based MR-specific class I triggers for surgery (left ventricular ejection fraction, end-systolic left ventricular diameter, symptoms-model 2), and third, adjusting additionally for guideline-based class II triggers (atrial fibrillation and systolic pulmonary artery pressure). In all 3 models, larger routinely-measured EROA and RVol were independently associated with worse survival Circulation. Table 2 ). In these multivariable analyses, routinely-measured EROA was strongly associated with mortality, carrying the largest χ 2 of all cardiac markers of outcome, surpassing all other guideline-based determinants of DMR outcome listed in Table 2 . Finally, routinely-measured EROA was incremental to these cardiac markers of outcome, adding power to mortality prediction in nested models (all P<0.0001). In nested models with comprehensive adjustment (model 2 or 3; Table 2 ), routinely-measured EROA addition improved models versus RVol (P<0.001) in predicting mortality.
Replacing the Charlson index by composite of chronic obstructive pulmonary disease, diabetes mellitus, chronic kidney disease, and cancer did not affect routinely-measured EROA link to mortality under medical treatment (adjusted hazard ratio, 1.19; 95% CI, 1.14-1.24; P<0.0001 per 10 mm 2 ). Larger routinely-measured EROA also remained associated with worse survival under medical treatment independent of biological data (hemoglobin, albumin, or creatinine), tricuspid regurgitation severity, right ventricle size and function, left atrial volume, and E/Eʹ ratio (all P<0.05).
To examine whether the competing event of surgery affected the determinants of mortality, a transitional model analysis was conducted and reported in the online-only Data Supplement. These models show a link between EROA and mortality under medical management similar to Cox proportional hazard analysis. (Figure 2 ). Excess mortality was also analyzed with routinely-measured EROA and RVol as continuous variables using spline curves of hazard ratio of death under medical treatment compared with expected mortality. This approach displays excess mortality (compared with the general population of matched age/sex) as hazard ratios >1 (Figure 3 ). This analysis shows no excess mortality with low routinely-measured EROA and RVol values (<20 mm 2 and <30 mL), whereas excess mortality (risk ratio >1) occurs with EROA ≥20 mm 2 , becomes notable with routinely-measured EROA ≥30 mm 2 and RVol ≥45 mL, and steadily increases above the traditional thresholds of 40 mm 2 and 60 mL with no plateau effect (Figure 3 ). This absence of plateau of risk suggests that individual values of routinelymeasured EROA provide risk prediction of excess mortality incremental to the average excess mortality for each DMR grade.
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Routine Quantitative MR Assessment Association to Excess Mortality
Routine EROA Survival Impact on Specific DMR Subsets
In a subgroup analysis, the impact on survival of routinely-measured EROA was confirmed in all subsets (Figure 4) . Among patients presenting with class I indication for surgery, the association between routinelymeasured EROA and mortality under medical treatment remained strong (Figure 4) . Hazard ratios for mortality under medical treatment attached to routinely-measured EROA (for 10 mm 2 increment) were 1.27 (P<0.0001) with left ventricular end-systolic diameter <40 mm and 1.23 (P=0.0001) with end-systolic diameter ≥40 mm; the hazard ratio was 1.40 (P<0.0001) with ejection fraction <60%, 1.25 (P<0.0001) with ejection fraction ≥60%, and 1.30 (P<0.0001) among symptomatic and 1.24 (P<0.0001) among asymptomatic patients. Results of the subgroup analysis were similar for RVol (Figure 3 ). In the subgroup of 1511 patients with any degree of DMR, asymptomatic, ejection fraction >60%, end-systolic diameter <40 mm, systolic pulmonary artery pressure ≤50 mm Hg, and in sinus rhythm, routinely-measured EROA remained associated with mortality under medical treatment in univariate analysis (hazard ratio, In each graph, the y axis represents the risk of excess mortality, with a risk of 1 representing the normal population mortality, whereas risk ratios <1 indicate survival better than expected and risk ratios >1 indicate excess mortality with a similar scale in both graphs. The x axis represents the levels of routinely-measured EROA (left) or RVol (right). The salient features of this graph are that, first, DMR with EROA <20 mm 2 are associated overall with normal survival under medical treatment (green zone); second, excess mortality appear for routinely-measured EROA ≈20 mm 2 (left lower arrow); and third, for EROA >20 mm 2 , excess mortality steadily increases with higher routinely-measured EROA, moderately (yellow zone), and then severely (red zone, right red arrow), underscoring the importance of accounting for the specific value (not just the grade) of routinely-measured EROA to evaluate the magnitude of risk incurred under medical management by patients with DMR. DMR indicates degenerative mitral regurgitation; EROA, effective regurgitant orifice area; MR, mitral regurgitation; and RVol, regurgitant volume. 
DMR Integrative and Quantitative Grading
DMR integrative grading is based on all DMR characteristics, including quantitative measures, and was none/trivial in 1245, mild in 229, moderate in 934, and severe in 1506. DMR integrative grading was associated with mortality under medical treatment (P<0.0001; hazard ratios shown in Table I in the online-only Data Supplement). However, in nested models with comprehensive adjustment (model 2 or 3 of Table 2 ), the addition of routinely-measured EROA to DMR integrative grading significantly improved models in predicting mortality (both P<0.0001). Furthermore, regarding excess mortality, spline curves displayed in Figure 3 show that individual EROA values add to the average excess mortality estimation by DMR grade (eg, the risk ratio of excess mortality attached to EROA 80 mm 2 is >3.0, whereas the average excess mortality for all severe DMR is 2.15). Hence, based on both spline curves and nested models, individual EROA values complement the discrete guideline-based grading of DMR.
Surgical Indications and Postoperative Survival
Among the 1263 patients who underwent mitral surgery (1166 repairs, 97 replacements), 65% had a class I or IIa specific trigger indicating surgery (left ventricular endsystolic diameter ≥40 in 20%, ejection fraction<60% in 18%, symptoms in 49%, pulmonary hypertension in 16%, and atrial fibrillation in 15%), and the remainder had a class IIa indication of high repair probability and low surgical risk. EROA was not a determinant of postoperative survival (hazard ratio for death after mitral surgery, 0.94; 95% CI, 0.86-1.01; P=0.11 per 10 mm 2 ).
Feasibility of MR Quantification
The quantified cohort (n=3914) of patients represented 65% of all patients diagnosed with isolated DMR during the same period (6068 patients; Figure I in the onlineonly Data Supplement). Stratified by MR severity, MR quantitation was obtained in 12.5% of patients with mild MR, 69% of patients with moderate MR, and 91% of patients with severe MR. Hence, among patients with moderate or severe MR, 82% had MR quantification. Characteristics of the nonquantified cohort are displayed in Table II in the online-only Data Supplement.
DISCUSSION
To our knowledge, this study is the first to report the clinical outcome of a large cohort of patients with a 
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Routine Practice of DMR Quantitation
The academic enterprise validating MR quantitation has long been recognized by clinical guidelines 4-7 based on studies endorsing technical measurements accuracy 18, 19, [24] [25] [26] and their impact on clinical outcome. [8] [9] [10] 27 However, these academic facts, real in the hands of experts, may not be transposable and scalable in highvolume clinical practice because quality control may be too complex or time-consuming. Publications of technical pitfalls 13, 17, [25] [26] [27] [28] [29] and insufficient reproducibility 14 cast doubt on the clinical validity of MR quantification. Magnetic resonance imaging studies 15, 16 reporting discordance with Doppler echocardiography reinforced these reliability concerns. Hence, the fundamental question of whether MR quantitation is scalable to routine clinical practice remained unanswered. This led to an incomplete penetrance of MR quantitative assessment among practitioners. 30, 31 Based on these knowledge gaps, we conducted a large-scale analysis of our routine clinical practice among unselected, consecutive patients with isolated DMR. This analysis validates the major clinical value of MR quantitation in daily clinical evaluation of patients with DMR. Routinely-measured EROA has the strongest link to survival under medical treatment among established cardiac determinants of outcome, especially left ventricular characteristics [32] [33] [34] and symptoms. 35 The importance of MR quantitation is crucial, confirmed using all statistical approaches, and quite stable, almost identical to our proof-of-concept expert study. 8 Although no method is without its pitfalls, 14, 25 the association between survival and MR quantitation is as valid by experts as a wide array of practitioners and is essential to DMR risk stratification in all patients' subsets.
DMR Assessment in Routine Practice: Quantitative, Categorical, or Both?
Questioning whether MR assessment should be quantitative, integrative, or both, our study suggests the answer is both. MR quantitation (routinely-measured EROA) provides survival prediction complementary to discrete grading in DMR evaluation. This is particularly important because EROA values were incorporated into reporting MR categorical grading showing that MR quantitation (routinely-measured EROA) should be reported in addition to the categorical grading. Unless MR is undoubtedly minimal, MR quantitation is an essential tool to refine outcome prediction.
DMR: Clinical Outcome and Importance of MR Severity
Our new result regarding excess mortality (compared with the general population) and its link to routinelymeasured EROA is also crucial. Patients with routinelymeasured EROA <20 mm 2 display no excess mortality and, unless exhibiting exceptional extrinsic risk factors, should be reassured. 11, 36 In patients with >20 mm 2 EROA, excess mortality appears and steadily increases with each increment in DMR severity without any threshold displaying a plateau of risk. 8 This new information is essential for the clinical management of DMR. Severe DMR cases with, for example, EROA of 40 mm 2 versus 80 mm 2 are not identical regarding risk of excess mortality and prompt decision for early surgery. 24 Likewise, in moderate DMR, in which the prognosis has seldom been studied, our data show that EROA values of 25 mm 2 versus 35 mm 2 are not identical regarding outcome. Impaired prognosis of moderate MR, suggested in a few small series, 8, 37, 38 emphasizes the risks of progression toward severe MR 37 and ventricular dysfunction despite careful follow-up. 38 Our findings of excess mortality in a large sample of moderate DMR show that some of these patients deserve close clinical attention and that a classification in severe versus nonsevere MR is not precise enough. DMR is a progressive disease. 37 If new modalities of intervention, such as robotically assisted repair or percutaneous treatment, prove to be extremely low-risk (<1% mortality), clinical trials in the upper range (≥30 mm 
Limitations and Strengths
Although our study used retrospective retrieval of patients with isolated DMR, all characteristics, echocardiographic, clinical, or otherwise, were collected at baseline and retrieved electronically without human interference. Not all patients had all methods performed, with the flow convergence method method used in 2622 patients, quantitative Doppler in 1193, and both in 1155, which reflects routine practice. Nevertheless, by either method, EROA was independently linked to survival (both P<0.01). Potential confounders were addressed by extensive adjustments in survival analysis and by focusing on the specific transition from diagnosis to death. Finally, the most relevant potential bias, whereby the performance of MR quantitation may be reflective of some prognosis underpinning, was addressed by examining the group without MR quantitation without uncovering any bias. Standard integrative grading includes MR as mild, moderate, or severe, but use of the terms mild-moderate (n=368) or moderatesevere (n=378) is possible. Use of these terms within integrative grading did not change our results, and the incremental prediction afforded by EROA individual values over integrative grading was confirmed (P=0.01).
Detailed analysis of cause of death to address mechanisms directly linked to DMR, in particular heart failure, cannot be addressed currently because of compliance with confidentiality regulations. But the powerful independent link between routinely-measured EROA and excess mortality, which is eliminated by mitral surgery, strongly suggests that this excess mortality is not random.
CONCLUSIONS
This large cohort with routine DMR quantitation uncovers 3 crucial concepts. First, Doppler echocardiographic MR quantitation, particularly EROA, shows a strong association with survival. This association persists throughout extensive adjustment and in all examined subsets of patients. Second, the results are representative not of a few selected experts but of day-to-day MR quantitation in the routine practice of a high-volume clinic. Third, routinely-measured EROA provides prognostic information complementary to categorical grading, with excess mortality appearing around routinely-measured EROA ≥20 mm 2 and increasing steadily thereafter. These crucial results emphasize the importance of conducting MR quantitation in routine clinical practice, not only to grade MR but also to report and account for actual individual EROA values in risk assessment and therapeutic decisions in DMR. On the basis of these results, clinical trials could be designed for interventional/surgical treatment testing for patients at risk of excess mortality.
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